{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T19:27:46Z","timestamp":1788895666316,"version":"build-2803163510"},"reference-count":22,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,10]]},"abstract":"<jats:p>\n                    Inflammatory myofibroblastic tumor (IMT) is a myofibroblastic\/fibroblastic neoplasm of intermediate malignant potential. It is frequently characterized by genetic fusion of\n                    <jats:italic toggle=\"yes\">ALK<\/jats:italic>\n                    with a variety of partner genes, which results in the activated ALK signaling pathway that can be targeted with kinase inhibitors. IMTs can occur in the gynecologic tract, with the uterus (corpus and cervix) being the most frequent site. Recent studies suggest that IMTs in the gynecologic tract are underrecognized, and a low-threshold for performing ALK immunohistochemistry has been proposed. The aim of this study was to evaluate the specificity of ALK immunohistochemistry for IMTs among uterine mesenchymal and mixed epithelial\/mesenchymal tumors. We performed ALK immunohistochemistry on 14 molecularly confirmed uterine IMTs and 260 other uterine pure mesenchymal and mixed epithelial\/mesenchymal tumors. Cases showing any positive cytoplasmic and\/or membranous staining of the tumor cells were considered to be ALK positive. All 14 IMTs were confirmed to harbor\n                    <jats:italic toggle=\"yes\">ALK<\/jats:italic>\n                    genetic fusion by RNA sequencing, and ALK immunostaining in the form of granular cytoplasmic positivity with paranuclear accentuation was observed in all 14 cases. ALK was negative (complete absence of staining) in all the other pure mesenchymal tumors and in all mixed epithelial\/mesenchymal tumors examined. Our findings show that ALK is a highly specific diagnostic immunohistochemical marker for\n                    <jats:italic toggle=\"yes\">ALK<\/jats:italic>\n                    fusion in uterine mesenchymal tumors. In the work-up of uterine mesenchymal tumors, particularly smooth muscle tumors showing myxoid stromal changes, a diagnosis of IMT should be strongly considered if ALK positivity is observed.\n                  <\/jats:p>","DOI":"10.1097\/pas.0000000000001120","type":"journal-article","created":{"date-parts":[[2018,7,14]],"date-time":"2018-07-14T06:58:13Z","timestamp":1531551493000},"page":"1353-1359","source":"Crossref","is-referenced-by-count":63,"title":["ALK Is a Specific Diagnostic Marker for Inflammatory Myofibroblastic Tumor of the Uterus"],"prefix":"10.1097","volume":"42","author":[{"given":"Nissreen","family":"Mohammad","sequence":"first","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, University of British Columbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josh D.","family":"Haimes","sequence":"additional","affiliation":[{"name":"ArcherDX Inc., Boulder, CO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Skyler","family":"Mishkin","sequence":"additional","affiliation":[{"name":"ArcherDX Inc., Boulder, CO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian A.","family":"Kudlow","sequence":"additional","affiliation":[{"name":"ArcherDX Inc., Boulder, CO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"May Ying","family":"Leong","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, KK Women\u2019s and Children\u2019s Hospital, Singapore, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung Hock","family":"Chew","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, KK Women\u2019s and Children\u2019s Hospital, Singapore, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleanor","family":"Koay","sequence":"additional","affiliation":[{"name":"Department of Histopathology, King Edward Memorial Hospital, Perth, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Whitehouse","sequence":"additional","affiliation":[{"name":"Sullivan Nicolaides Pathology, Brisbane, Qld, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nichola","family":"Cope","sequence":"additional","affiliation":[{"name":"Department of Pathology, Royal Devon and Exeter Hospital, Exeter"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rola H.","family":"Ali","sequence":"additional","affiliation":[{"name":"Department of Pathology, Kuwait University, Kuwait City, Kuwait"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"K\u00f6bel","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Calgary Laboratory Services and University of Calgary, Calgary, AB, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin J.R.","family":"Stewart","sequence":"additional","affiliation":[{"name":"Department of Histopathology, King Edward Memorial Hospital, Perth, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. Glenn","family":"McCluggage","sequence":"additional","affiliation":[{"name":"Department of Pathology, Belfast Health and Social Care Trust, Belfast, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-Han","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, University of British Columbia"},{"name":"Department of Pathology and Laboratory Medicine, BC Cancer, Vancouver, BC"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-20230922","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1097\/01.pas.0000172189.02424.91","article-title":"Inflammatory myofibroblastic tumor of the uterus: a clinicopathologic study of 6 cases emphasizing distinction from aggressive mesenchymal tumors","volume":"29","author":"Rabban","year":"2005","journal-title":"Am J Surg Pathol"},{"key":"R3-20230922","doi-asserted-by":"crossref","first-page":"623","DOI":"10.5858\/arpa.2011-0341-OA","article-title":"ALK-1 protein expression and ALK gene rearrangements aid in the diagnosis of inflammatory myofibroblastic tumors of the female genital tract","volume":"136","author":"Fuehrer","year":"2012","journal-title":"Arch Pathol Lab Med"},{"key":"R4-20230922","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1097\/PAS.0000000000000330","article-title":"Inflammatory myofibroblastic tumor of the uterus: clinical and pathologic review of 10 cases including a subset with aggressive clinical course","volume":"39","author":"Parra-Herran","year":"2015","journal-title":"Am J Surg Pathol"},{"key":"R5-20230922","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1097\/PAS.0000000000000801","article-title":"Uterine inflammatory myofibroblastic tumors frequently harbor ALK fusions with IGFBP5 and THBS1","volume":"41","author":"Haimes","year":"2017","journal-title":"Am J Surg Pathol"},{"key":"R6-20230922","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1097\/PAS.0000000000000909","article-title":"Inflammatory myofibroblastic tumors of the female genital tract are under-recognized: a low threshold for ALK immunohistochemistry is required","volume":"41","author":"Pickett","year":"2017","journal-title":"Am J Surg Pathol"},{"key":"R7-20230922","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1038\/modpathol.2017.69","article-title":"Inflammatory myofibroblastic tumor of the uterus: a clinicopathological, immunohistochemical, and molecular analysis of 13 cases highlighting their broad morphologic spectrum","volume":"30","author":"Bennett","year":"2017","journal-title":"Mod Pathol"},{"key":"R8-20230922","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1097\/PAS.0000000000000593","article-title":"Myxoid leiomyosarcoma of the uterus: a clinicopathologic analysis of 30 cases and review of the literature with reappraisal of its distinction from other uterine myxoid mesenchymal neoplasms","volume":"40","author":"Parra-Herran","year":"2016","journal-title":"Am J Surg Pathol"},{"key":"R9-20230922","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1067\/S0002-9378(03)00208-4","article-title":"Inflammatory myoblastic tumor of the uterus and interleukin-6","volume":"189","author":"Azuno","year":"2003","journal-title":"Am J Obstet Gynecol"},{"key":"R10-20230922","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1200\/JCO.2013.48.8304","article-title":"Uterine inflammatory myofibroblastic tumor in a 10-year-old girl presenting as polypoid mass","volume":"33","author":"Fraggetta","year":"2015","journal-title":"J Clin Oncol"},{"key":"R11-20230922","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.gynor.2013.07.007","article-title":"Extrauterine inflammatory myofibroblastic tumor: A case report","volume":"6","author":"Kushnir","year":"2013","journal-title":"Gynecol Oncol Case Rep"},{"key":"R12-20230922","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.ejogrb.2011.02.016","article-title":"Hysteroscopic excision of inflammatory myofibroblastic tumor of the uterus: a case report and brief review","volume":"157","author":"Olgan","year":"2011","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"R13-20230922","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1111\/j.1440-1827.2006.02018.x","article-title":"Inflammatory myofibroblastic tumor of the uterus with prominent myxoid change","volume":"56","author":"Shintaku","year":"2006","journal-title":"Pathol Int"},{"key":"R14-20230922","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s13045-015-0160-2","article-title":"STUMP un\u201cstumped\u201d: anti-tumor response to anaplastic lymphoma kinase (ALK) inhibitor based targeted therapy in uterine inflammatory myofibroblastic tumor with myxoid features harboring DCTN1-ALK fusion","volume":"8","author":"Subbiah","year":"2015","journal-title":"J Hematol Oncol"},{"key":"R15-20230922","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.humpath.2003.12.004","article-title":"Expression of anaplastic lymphoma kinase in soft tissue tumors: an immunohistochemical and molecular study of 249 cases","volume":"35","author":"Li","year":"2004","journal-title":"Hum Pathol"},{"key":"R16-20230922","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1097\/01.MP.0000026615.04130.1F","article-title":"Expression of ALK1 and p80 in inflammatory myofibroblastic tumor and its mesenchymal mimics: a study of 135 cases","volume":"15","author":"Cessna","year":"2002","journal-title":"Mod Pathol"},{"key":"R17-20230922","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1097\/00000478-200111000-00003","article-title":"Anaplastic lymphoma kinase (ALK) expression in the inflammatory myofibroblastic tumor: a comparative immunohistochemical study","volume":"25","author":"Cook","year":"2001","journal-title":"Am J Surg Pathol"},{"key":"R18-20230922","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/S0002-9440(10)61711-7","article-title":"Fusion of the ALK gene to the clathrin heavy chain gene, CLTC, in inflammatory myofibroblastic tumor","volume":"159","author":"Bridge","year":"2001","journal-title":"Am J Pathol"},{"key":"R19-20230922","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/gcc.10177","article-title":"Fusion of ALK to the Ran-binding protein 2 (RANBP2) gene in inflammatory myofibroblastic tumor","volume":"37","author":"Ma","year":"2003","journal-title":"Genes Chromosomes Cancer"},{"key":"R20-20230922","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/S0002-9440(10)64550-6","article-title":"TPM3-ALK and TPM4-ALK oncogenes in inflammatory myofibroblastic tumors","volume":"157","author":"Lawrence","year":"2000","journal-title":"Am J Pathol"},{"key":"R21-20230922","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1097\/PAS.0000000000001055","article-title":"NTRK fusions define a novel uterine sarcoma subtype with features of fibrosarcoma","volume":"42","author":"Chiang","year":"2018","journal-title":"Am J Surg Pathol"},{"key":"R22-20230922","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/his.12910","article-title":"ALK, ROS1 and NTRK3 gene rearrangements in inflammatory myofibroblastic tumours","volume":"69","author":"Yamamoto","year":"2016","journal-title":"Histopathology"},{"key":"R23-20230922","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1097\/PAS.0000000000000677","article-title":"ETV6-NTRK3 is expressed in a subset of ALK-negative inflammatory myofibroblastic tumors","volume":"40","author":"Alassiri","year":"2016","journal-title":"Am J Surg Pathol"}],"container-title":["American Journal of Surgical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00000478-201810000-00009","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T18:28:55Z","timestamp":1695407335000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00000478-201810000-00009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":22,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/pas.0000000000001120","relation":{},"ISSN":["0147-5185"],"issn-type":[{"value":"0147-5185","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]}}}